Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Sep 08, 2014 12:05pm
252 Views
Post# 22915826

RE:From Fundamentals6 on the Other Board: New Zenith Hire

RE:From Fundamentals6 on the Other Board: New Zenith HireSanFran, thanks for the post.

The hiring of Dr. Joy Zhu is another sign of how well things are moving at Zenith and how hot this field is and will be into the long term future. I hear about epi-genetics regularly in media such as Quirks and Quarks which is a very legitmate science show on CBC Radio in Canada.

It is also a clear signal that they have the financing plans in place at Zenith...whatever those plans may be. My hope is for a financing plan that provides liquidity at a value appropriate to the potential of each of the epi-genetic platforms both now and to come in the future. We deserve to be able to recoup the value we lost when the value of these assets was transferred to a private company.

So things are moving rapidly ahead at Zenith with the new CEO. The main concern now is lack of action at RVX. I'm beginning to feel that Don's top priority should be to replace himself with someone that can move RVX to the next level. This could even have an impact of repositioning the RVX brand by getting rid of Don's negative baggage. Add to this effective communications and we could see some action.

Anyway, good things are happening and the only way we know this is because of the great detective work of you posters (and not effective communications from RVX).

Very frustrated but sort of hopeful      :(

GLTA
Cheers
toinv


Bullboard Posts